Literature DB >> 16274744

Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.

Markus Rihl1, Matthias Stoll, Kai Ulbricht, Franz-Christoph Bange, Reinhold-Ernst Schmidt.   

Abstract

We present a 42-year-old man who was admitted with worsening of his general condition and facial skin lesions. He had previously been diagnosed with HIV infection and visceral leishmaniasis (VL). Diagnostic work-up revealed a new relapse of VL paralleled by the diagnosis of post-kala-azar dermal leishmaniasis (PKDL). The patient was treated with IV liposomal amphotericin B as well as sodium stibogluconate followed by oral hexadecylphosphocholine (miltefosine) over a period of 9 months. PKDL lesions began to disappear after 8 months of treatment. In addition, severe and relapsing VL so far remains in remission. This case demonstrates successful treatment of PKDL and relapsing VL in a Western European patient with HIV infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16274744     DOI: 10.1016/j.jinf.2005.09.015

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  8 in total

1.  Disseminated cutaneous leishmaniasis resembling post-kala-azar dermal leishmaniasis caused by Leishmania donovani in three patients co-infected with visceral leishmaniasis and human immunodeficiency virus/acquired immunodeficiency syndrome in Ethiopia.

Authors:  Tesfaye Gelanew; Zewdu Hurissa; Ermias Diro; Aysheshm Kassahun; Katrin Kuhls; Gabriele Schönian; Asrat Hailu
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

Review 2.  Leishmaniasis as a Manifestation of Immune Reconstitution Inflammatory Syndrome (IRIS) in HIV-Infected Patients: A Literature Review.

Authors:  Roberto Badaró; Larissa O Gonçalves; Luana L Gois; Zuinara Pereira Gusmão Maia; Constance Benson; Maria Fernanda Rios Grassi
Journal:  J Int Assoc Provid AIDS Care       Date:  2014-10-20

Review 3.  The immune reconstitution inflammatory syndrome related to HIV co-infections: a review.

Authors:  D Huis in 't Veld; H-Y Sun; C-C Hung; R Colebunders
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-02       Impact factor: 3.267

Review 4.  The relationship between leishmaniasis and AIDS: the second 10 years.

Authors:  Jorge Alvar; Pilar Aparicio; Abraham Aseffa; Margriet Den Boer; Carmen Cañavate; Jean-Pierre Dedet; Luigi Gradoni; Rachel Ter Horst; Rogelio López-Vélez; Javier Moreno
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

Review 5.  PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses.

Authors:  Eduard E Zijlstra
Journal:  PLoS Negl Trop Dis       Date:  2014-11-20

6.  Therapeutic Modalities in Post Kala-azar Dermal Leishmaniasis: A Systematic Review of the Effectiveness and Safety of the Treatment Options.

Authors:  Adrija Datta; Indrashis Podder; Anupam Das; Amrita Sil; Nilay Kanti Das
Journal:  Indian J Dermatol       Date:  2021 Jan-Feb       Impact factor: 1.494

7.  Atypical Presentation of PKDL due to Leishmania infantum in an HIV-Infected Patient with Relapsing Visceral Leishmaniasis.

Authors:  Benedetto Maurizio Celesia; Bruno Cacopardo; Daniela Massimino; Maria Gussio; Salvatore Tosto; Giuseppe Nunnari; Marilia Rita Pinzone
Journal:  Case Rep Infect Dis       Date:  2014-08-14

8.  Study on the safety and efficacy of miltefosine for the treatment of children and adolescents with post-kala-azar dermal leishmaniasis in Bangladesh, and an association of serum vitamin E and exposure to arsenic with post-kala-azar dermal leishmaniasis: an open clinical trial and case-control study protocol.

Authors:  D Mondal; M G Hasnain; M S Hossain; D Ghosh; P Ghosh; H Hossain; J Baker; R Nath; R Haque; G Matlashewski; S Hamano
Journal:  BMJ Open       Date:  2016-05-17       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.